Denali Therapeutics shared details from its earnings call for the second quarter of 2026.

Oct 12, 2026, 8:05 AM ETResultsRead the original at Benzinga

Good for DNLI

Denali Therapeutics reported $3.6 million in Avlea sales in its first full quarter and over $1.1 billion in cash and securities. Sales and 2 Alzheimer’s programs entering testing support a favorable outlook, though their first study data are expected in 2027.

DNLI · Denali Therapeutics

AI read · Good for DNLI

The AI's read

This gives Denali its first product-sales base and shows its brain-delivery approach has produced an approved treatment. The Alzheimer’s programs add possible future medicines, but their first study data are not expected until 2027. Cash and securities give Denali funds to keep developing treatments.

Get alerts for DNLI

Follow Denali Therapeutics (DNLI) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for DNLI

Free on the App Store and Google Play, or on the web.